nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.105	0.282	CbGbCtD
Everolimus—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0708	0.19	CbGbCtD
Everolimus—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0675	0.182	CbGbCtD
Everolimus—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0602	0.162	CbGbCtD
Everolimus—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0353	0.0949	CbGbCtD
Everolimus—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0333	0.0897	CbGbCtD
Everolimus—MTOR—leg—chronic obstructive pulmonary disease	0.0299	0.349	CbGeAlD
Everolimus—MTOR—respiratory system—chronic obstructive pulmonary disease	0.00742	0.0867	CbGeAlD
Everolimus—FKBP1A—respiratory system—chronic obstructive pulmonary disease	0.00667	0.0779	CbGeAlD
Everolimus—MTOR—connective tissue—chronic obstructive pulmonary disease	0.00653	0.0763	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—chronic obstructive pulmonary disease	0.00597	0.0698	CbGeAlD
Everolimus—FKBP1A—connective tissue—chronic obstructive pulmonary disease	0.00587	0.0686	CbGeAlD
Everolimus—FKBP1A—bronchus—chronic obstructive pulmonary disease	0.00549	0.0642	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—chronic obstructive pulmonary disease	0.00537	0.0628	CbGeAlD
Everolimus—FKBP1A—trachea—chronic obstructive pulmonary disease	0.00493	0.0576	CbGeAlD
Everolimus—MTOR—lung—chronic obstructive pulmonary disease	0.00394	0.046	CbGeAlD
Everolimus—FKBP1A—lung—chronic obstructive pulmonary disease	0.00354	0.0414	CbGeAlD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB3—chronic obstructive pulmonary disease	0.000549	0.00388	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KL—chronic obstructive pulmonary disease	0.000545	0.00385	CbGpPWpGaD
Everolimus—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000544	0.00384	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	0.000529	0.00373	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KL—chronic obstructive pulmonary disease	0.000521	0.00368	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KL—chronic obstructive pulmonary disease	0.000518	0.00366	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KL—chronic obstructive pulmonary disease	0.000515	0.00364	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KL—chronic obstructive pulmonary disease	0.000513	0.00362	CbGpPWpGaD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000509	0.0036	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	0.000507	0.00358	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KL—chronic obstructive pulmonary disease	0.000505	0.00357	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000499	0.00352	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—PLAU—chronic obstructive pulmonary disease	0.000499	0.00352	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL1B—chronic obstructive pulmonary disease	0.00049	0.00346	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KL—chronic obstructive pulmonary disease	0.000483	0.00341	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KL—chronic obstructive pulmonary disease	0.000483	0.00341	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KL—chronic obstructive pulmonary disease	0.000483	0.00341	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—NOS3—chronic obstructive pulmonary disease	0.000482	0.0034	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	0.000478	0.00338	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KL—chronic obstructive pulmonary disease	0.000478	0.00338	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KL—chronic obstructive pulmonary disease	0.000474	0.00335	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KL—chronic obstructive pulmonary disease	0.000472	0.00333	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KL—chronic obstructive pulmonary disease	0.000447	0.00315	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—LY96—chronic obstructive pulmonary disease	0.000439	0.0031	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB3—chronic obstructive pulmonary disease	0.000434	0.00306	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RAPGEF3—chronic obstructive pulmonary disease	0.000434	0.00306	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KL—chronic obstructive pulmonary disease	0.000427	0.00302	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB3—chronic obstructive pulmonary disease	0.000415	0.00293	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—IL1B—chronic obstructive pulmonary disease	0.00041	0.0029	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—chronic obstructive pulmonary disease	0.000409	0.00289	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—ERBB3—chronic obstructive pulmonary disease	0.000409	0.00288	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—chronic obstructive pulmonary disease	0.000408	0.00288	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.000406	0.00287	CbGpPWpGaD
Everolimus—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0004	0.00282	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	0.000394	0.00278	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—ERBB3—chronic obstructive pulmonary disease	0.00039	0.00275	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—chronic obstructive pulmonary disease	0.000389	0.00275	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB3—chronic obstructive pulmonary disease	0.000388	0.00274	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	0.000387	0.00273	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB3—chronic obstructive pulmonary disease	0.000386	0.00273	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—SERPINE1—chronic obstructive pulmonary disease	0.000386	0.00272	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB3—chronic obstructive pulmonary disease	0.000384	0.00271	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—chronic obstructive pulmonary disease	0.000381	0.00269	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—chronic obstructive pulmonary disease	0.00038	0.00268	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB3—chronic obstructive pulmonary disease	0.000379	0.00268	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	0.000368	0.0026	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—chronic obstructive pulmonary disease	0.000363	0.00256	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB3—chronic obstructive pulmonary disease	0.000362	0.00255	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB3—chronic obstructive pulmonary disease	0.000362	0.00255	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB3—chronic obstructive pulmonary disease	0.000362	0.00255	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB3—chronic obstructive pulmonary disease	0.000358	0.00253	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB3—chronic obstructive pulmonary disease	0.000355	0.00251	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB3—chronic obstructive pulmonary disease	0.000354	0.0025	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HDAC2—chronic obstructive pulmonary disease	0.000354	0.0025	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—MMP9—chronic obstructive pulmonary disease	0.000353	0.00249	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—chronic obstructive pulmonary disease	0.000349	0.00246	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—TGFB1—chronic obstructive pulmonary disease	0.000345	0.00243	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NOS3—chronic obstructive pulmonary disease	0.000342	0.00242	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000341	0.00241	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—EGFR—chronic obstructive pulmonary disease	0.000338	0.00239	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB3—chronic obstructive pulmonary disease	0.000335	0.00236	CbGpPWpGaD
Everolimus—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.000833	CcSEcCtD
Everolimus—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000333	0.000832	CcSEcCtD
Everolimus—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000332	0.000827	CcSEcCtD
Everolimus—Infection—Formoterol—chronic obstructive pulmonary disease	0.000332	0.000827	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000331	0.00234	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KL—chronic obstructive pulmonary disease	0.000329	0.00232	CbGpPWpGaD
Everolimus—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.00082	CcSEcCtD
Everolimus—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.00082	CcSEcCtD
Everolimus—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.00082	CcSEcCtD
Everolimus—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000328	0.000818	CcSEcCtD
Everolimus—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.000817	CcSEcCtD
Everolimus—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000327	0.000817	CcSEcCtD
Everolimus—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000327	0.000817	CcSEcCtD
Everolimus—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000327	0.000816	CcSEcCtD
Everolimus—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000327	0.000816	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—chronic obstructive pulmonary disease	0.000327	0.00231	CbGpPWpGaD
Everolimus—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000326	0.000813	CcSEcCtD
Everolimus—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000326	0.000813	CcSEcCtD
Everolimus—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000325	0.00081	CcSEcCtD
Everolimus—Infection—Montelukast—chronic obstructive pulmonary disease	0.000325	0.00081	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	0.000325	0.00229	CbGpPWpGaD
Everolimus—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000324	0.000809	CcSEcCtD
Everolimus—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000324	0.000809	CcSEcCtD
Everolimus—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000324	0.000809	CcSEcCtD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000323	0.00228	CbGpPWpGaD
Everolimus—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000323	0.000806	CcSEcCtD
Everolimus—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.000802	CcSEcCtD
Everolimus—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000321	0.0008	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB3—chronic obstructive pulmonary disease	0.00032	0.00226	CbGpPWpGaD
Everolimus—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00032	0.000799	CcSEcCtD
Everolimus—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.00032	0.000798	CcSEcCtD
Everolimus—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000319	0.000797	CcSEcCtD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000319	0.00225	CbGpPWpGaD
Everolimus—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000317	0.000792	CcSEcCtD
Everolimus—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.000786	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—chronic obstructive pulmonary disease	0.000313	0.00221	CbGpPWpGaD
Everolimus—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000313	0.000781	CcSEcCtD
Everolimus—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000312	0.000778	CcSEcCtD
Everolimus—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000312	0.000778	CcSEcCtD
Everolimus—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000312	0.000777	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—GSTP1—chronic obstructive pulmonary disease	0.000311	0.0022	CbGpPWpGaD
Everolimus—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00031	0.000774	CcSEcCtD
Everolimus—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00031	0.000773	CcSEcCtD
Everolimus—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000309	0.000771	CcSEcCtD
Everolimus—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.000767	CcSEcCtD
Everolimus—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000307	0.000766	CcSEcCtD
Everolimus—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000306	0.000764	CcSEcCtD
Everolimus—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000305	0.00076	CcSEcCtD
Everolimus—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000305	0.00076	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000304	0.000759	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000304	0.000759	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000302	0.00213	CbGpPWpGaD
Everolimus—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000302	0.000753	CcSEcCtD
Everolimus—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000302	0.000753	CcSEcCtD
Everolimus—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.000749	CcSEcCtD
Everolimus—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.0003	0.000749	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000298	0.000743	CcSEcCtD
Everolimus—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000298	0.000742	CcSEcCtD
Everolimus—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.000742	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	0.000297	0.0021	CbGpPWpGaD
Everolimus—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000297	0.00074	CcSEcCtD
Everolimus—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000297	0.00074	CcSEcCtD
Everolimus—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000296	0.000738	CcSEcCtD
Everolimus—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000295	0.000735	CcSEcCtD
Everolimus—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.000735	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000294	0.00208	CbGpPWpGaD
Everolimus—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.000733	CcSEcCtD
Everolimus—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000294	0.000733	CcSEcCtD
Everolimus—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000293	0.000732	CcSEcCtD
Everolimus—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000293	0.00073	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000292	0.00206	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—chronic obstructive pulmonary disease	0.000291	0.00205	CbGpPWpGaD
Everolimus—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000291	0.00205	CbGpPWpGaD
Everolimus—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000291	0.000725	CcSEcCtD
Everolimus—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00029	0.000723	CcSEcCtD
Everolimus—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000288	0.000719	CcSEcCtD
Everolimus—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.000719	CcSEcCtD
Everolimus—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000288	0.000718	CcSEcCtD
Everolimus—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.000718	CcSEcCtD
Everolimus—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000288	0.000718	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.000716	CcSEcCtD
Everolimus—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000285	0.000712	CcSEcCtD
Everolimus—Pain—Formoterol—chronic obstructive pulmonary disease	0.000285	0.000712	CcSEcCtD
Everolimus—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000285	0.000712	CcSEcCtD
Everolimus—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000285	0.000712	CcSEcCtD
Everolimus—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.000711	CcSEcCtD
Everolimus—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.000706	CcSEcCtD
Everolimus—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000282	0.000704	CcSEcCtD
Everolimus—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000282	0.000703	CcSEcCtD
Everolimus—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.000701	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000281	0.00198	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.00028	0.00198	CbGpPWpGaD
Everolimus—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.000699	CcSEcCtD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—chronic obstructive pulmonary disease	0.00028	0.00198	CbGpPWpGaD
Everolimus—Pain—Montelukast—chronic obstructive pulmonary disease	0.00028	0.000697	CcSEcCtD
Everolimus—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000279	0.000697	CcSEcCtD
Everolimus—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000279	0.000696	CcSEcCtD
Everolimus—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000278	0.000693	CcSEcCtD
Everolimus—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.000692	CcSEcCtD
Everolimus—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000276	0.00069	CcSEcCtD
Everolimus—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000276	0.000689	CcSEcCtD
Everolimus—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000275	0.000687	CcSEcCtD
Everolimus—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000275	0.000686	CcSEcCtD
Everolimus—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000275	0.000686	CcSEcCtD
Everolimus—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000275	0.000685	CcSEcCtD
Everolimus—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.000683	CcSEcCtD
Everolimus—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000274	0.000683	CcSEcCtD
Everolimus—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000273	0.000682	CcSEcCtD
Everolimus—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000273	0.000681	CcSEcCtD
Everolimus—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000273	0.000681	CcSEcCtD
Everolimus—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000273	0.00068	CcSEcCtD
Everolimus—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.000679	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—chronic obstructive pulmonary disease	0.000272	0.00192	CbGpPWpGaD
Everolimus—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.000678	CcSEcCtD
Everolimus—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000269	0.000672	CcSEcCtD
Everolimus—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000269	0.000672	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	0.000268	0.00189	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000267	0.000667	CcSEcCtD
Everolimus—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000264	0.000658	CcSEcCtD
Everolimus—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.000658	CcSEcCtD
Everolimus—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000264	0.000658	CcSEcCtD
Everolimus—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.000658	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000263	0.00186	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAPGEF3—chronic obstructive pulmonary disease	0.000263	0.00186	CbGpPWpGaD
Everolimus—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000263	0.000656	CcSEcCtD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000262	0.00185	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—chronic obstructive pulmonary disease	0.000261	0.00184	CbGpPWpGaD
Everolimus—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000261	0.000651	CcSEcCtD
Everolimus—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00026	0.00065	CcSEcCtD
Everolimus—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00026	0.00065	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—chronic obstructive pulmonary disease	0.00026	0.00184	CbGpPWpGaD
Everolimus—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.000648	CcSEcCtD
Everolimus—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000259	0.000646	CcSEcCtD
Everolimus—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000258	0.000645	CcSEcCtD
Everolimus—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000258	0.000645	CcSEcCtD
Everolimus—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.000643	CcSEcCtD
Everolimus—MTOR—Immune System—LY96—chronic obstructive pulmonary disease	0.000256	0.00181	CbGpPWpGaD
Everolimus—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000256	0.000638	CcSEcCtD
Everolimus—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000255	0.000636	CcSEcCtD
Everolimus—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.000635	CcSEcCtD
Everolimus—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000254	0.000634	CcSEcCtD
Everolimus—MTOR—PI-3K cascade—EGFR—chronic obstructive pulmonary disease	0.000252	0.00178	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	0.00025	0.00177	CbGpPWpGaD
Everolimus—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.000622	CcSEcCtD
Everolimus—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.000622	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—VEGFA—chronic obstructive pulmonary disease	0.000247	0.00174	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB3—chronic obstructive pulmonary disease	0.000246	0.00174	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—chronic obstructive pulmonary disease	0.000246	0.00174	CbGpPWpGaD
Everolimus—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000246	0.000613	CcSEcCtD
Everolimus—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000246	0.000613	CcSEcCtD
Everolimus—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000246	0.000613	CcSEcCtD
Everolimus—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000611	CcSEcCtD
Everolimus—MTOR—GAB1 signalosome—EGFR—chronic obstructive pulmonary disease	0.000244	0.00173	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—chronic obstructive pulmonary disease	0.000243	0.00172	CbGpPWpGaD
Everolimus—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000243	0.000607	CcSEcCtD
Everolimus—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000241	0.000601	CcSEcCtD
Everolimus—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000239	0.000597	CcSEcCtD
Everolimus—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.000597	CcSEcCtD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—chronic obstructive pulmonary disease	0.000239	0.00169	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—chronic obstructive pulmonary disease	0.000239	0.00169	CbGpPWpGaD
Everolimus—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000236	0.000589	CcSEcCtD
Everolimus—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.000589	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000588	CcSEcCtD
Everolimus—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000588	CcSEcCtD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000235	0.00166	CbGpPWpGaD
Everolimus—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000235	0.000585	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—chronic obstructive pulmonary disease	0.000233	0.00165	CbGpPWpGaD
Everolimus—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000232	0.00058	CcSEcCtD
Everolimus—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.000579	CcSEcCtD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000232	0.00164	CbGpPWpGaD
Everolimus—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000231	0.000577	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000229	0.00162	CbGpPWpGaD
Everolimus—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000228	0.00057	CcSEcCtD
Everolimus—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000228	0.00057	CcSEcCtD
Everolimus—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000565	CcSEcCtD
Everolimus—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.000564	CcSEcCtD
Everolimus—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000224	0.000558	CcSEcCtD
Everolimus—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.000556	CcSEcCtD
Everolimus—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.000553	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	0.000221	0.00156	CbGpPWpGaD
Everolimus—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000221	0.000551	CcSEcCtD
Everolimus—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.000551	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—IL6—chronic obstructive pulmonary disease	0.000217	0.00153	CbGpPWpGaD
Everolimus—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000216	0.000539	CcSEcCtD
Everolimus—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000216	0.000539	CcSEcCtD
Everolimus—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.000538	CcSEcCtD
Everolimus—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000213	0.000531	CcSEcCtD
Everolimus—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.000529	CcSEcCtD
Everolimus—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000212	0.000529	CcSEcCtD
Everolimus—MTOR—IRS-related events—IL6—chronic obstructive pulmonary disease	0.000211	0.00149	CbGpPWpGaD
Everolimus—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.000525	CcSEcCtD
Everolimus—Rash—Formoterol—chronic obstructive pulmonary disease	0.00021	0.000525	CcSEcCtD
Everolimus—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.000525	CcSEcCtD
Everolimus—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00021	0.000525	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—chronic obstructive pulmonary disease	0.000209	0.00148	CbGpPWpGaD
Everolimus—Headache—Formoterol—chronic obstructive pulmonary disease	0.000209	0.000522	CcSEcCtD
Everolimus—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.000522	CcSEcCtD
Everolimus—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000209	0.000521	CcSEcCtD
Everolimus—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000209	0.000521	CcSEcCtD
Everolimus—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00052	CcSEcCtD
Everolimus—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000208	0.00052	CcSEcCtD
Everolimus—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000208	0.000519	CcSEcCtD
Everolimus—Rash—Montelukast—chronic obstructive pulmonary disease	0.000206	0.000514	CcSEcCtD
Everolimus—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000206	0.000514	CcSEcCtD
Everolimus—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000205	0.000513	CcSEcCtD
Everolimus—Headache—Montelukast—chronic obstructive pulmonary disease	0.000205	0.000511	CcSEcCtD
Everolimus—MTOR—IGF1R signaling cascade—IL6—chronic obstructive pulmonary disease	0.000204	0.00144	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—chronic obstructive pulmonary disease	0.000204	0.00144	CbGpPWpGaD
Everolimus—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000203	0.000506	CcSEcCtD
Everolimus—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000202	0.000505	CcSEcCtD
Everolimus—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000202	0.000504	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—chronic obstructive pulmonary disease	0.0002	0.00142	CbGpPWpGaD
Everolimus—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.0005	CcSEcCtD
Everolimus—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.000498	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TLR2—chronic obstructive pulmonary disease	0.000199	0.00141	CbGpPWpGaD
Everolimus—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.000496	CcSEcCtD
Everolimus—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000199	0.000495	CcSEcCtD
Everolimus—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.000495	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000198	0.0014	CbGpPWpGaD
Everolimus—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.000495	CcSEcCtD
Everolimus—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000198	0.000495	CcSEcCtD
Everolimus—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.000493	CcSEcCtD
Everolimus—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.000486	CcSEcCtD
Everolimus—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000194	0.000484	CcSEcCtD
Everolimus—FKBP1A—Disease—HDAC2—chronic obstructive pulmonary disease	0.000193	0.00136	CbGpPWpGaD
Everolimus—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000192	0.000479	CcSEcCtD
Everolimus—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000191	0.000477	CcSEcCtD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000191	0.00135	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—chronic obstructive pulmonary disease	0.000189	0.00133	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KL—chronic obstructive pulmonary disease	0.000187	0.00132	CbGpPWpGaD
Everolimus—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.000467	CcSEcCtD
Everolimus—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.000465	CcSEcCtD
Everolimus—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000186	0.000464	CcSEcCtD
Everolimus—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000461	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000185	0.0013	CbGpPWpGaD
Everolimus—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000459	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—chronic obstructive pulmonary disease	0.000183	0.0013	CbGpPWpGaD
Everolimus—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000182	0.000453	CcSEcCtD
Everolimus—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.000451	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—chronic obstructive pulmonary disease	0.000181	0.00128	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—chronic obstructive pulmonary disease	0.00018	0.00127	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KL—chronic obstructive pulmonary disease	0.00018	0.00127	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KL—chronic obstructive pulmonary disease	0.000179	0.00127	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000178	0.00126	CbGpPWpGaD
Everolimus—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000178	0.000444	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—EGFR—chronic obstructive pulmonary disease	0.000178	0.00125	CbGpPWpGaD
Everolimus—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000176	0.00044	CcSEcCtD
Everolimus—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000175	0.000436	CcSEcCtD
Everolimus—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000431	CcSEcCtD
Everolimus—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000428	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—IL6—chronic obstructive pulmonary disease	0.000171	0.0012	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.00017	0.0012	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—chronic obstructive pulmonary disease	0.00017	0.0012	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—chronic obstructive pulmonary disease	0.000169	0.0012	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—chronic obstructive pulmonary disease	0.000169	0.00119	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—chronic obstructive pulmonary disease	0.000169	0.00119	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—chronic obstructive pulmonary disease	0.000168	0.00119	CbGpPWpGaD
Everolimus—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000418	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000168	0.00118	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—chronic obstructive pulmonary disease	0.000167	0.00118	CbGpPWpGaD
Everolimus—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000417	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000166	0.00117	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—chronic obstructive pulmonary disease	0.000165	0.00116	CbGpPWpGaD
Everolimus—Tacrolimus—ALB—chronic obstructive pulmonary disease	0.000164	1	CrCbGaD
Everolimus—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.000408	CcSEcCtD
Everolimus—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000408	CcSEcCtD
Everolimus—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.000405	CcSEcCtD
Everolimus—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000404	CcSEcCtD
Everolimus—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000401	CcSEcCtD
Everolimus—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000401	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	0.000157	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	0.000157	0.00111	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	0.000157	0.00111	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CXCL8—chronic obstructive pulmonary disease	0.000156	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	0.000156	0.0011	CbGpPWpGaD
Everolimus—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.000386	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	0.000154	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	0.000154	0.00109	CbGpPWpGaD
Everolimus—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000378	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	0.00015	0.00106	CbGpPWpGaD
Everolimus—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000373	CcSEcCtD
Everolimus—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.000372	CcSEcCtD
Everolimus—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000371	CcSEcCtD
Everolimus—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000369	CcSEcCtD
Everolimus—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000367	CcSEcCtD
Everolimus—MTOR—B Cell Activation—EGFR—chronic obstructive pulmonary disease	0.000145	0.00103	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—chronic obstructive pulmonary disease	0.000145	0.00102	CbGpPWpGaD
Everolimus—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000362	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	0.000145	0.00102	CbGpPWpGaD
Everolimus—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000144	0.00036	CcSEcCtD
Everolimus—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000141	0.000353	CcSEcCtD
Everolimus—MTOR—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	0.000141	0.000992	CbGpPWpGaD
Everolimus—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000348	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000139	0.000983	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	0.000139	0.000983	CbGpPWpGaD
Everolimus—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000347	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	0.000139	0.000979	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000137	0.00097	CbGpPWpGaD
Everolimus—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000342	CcSEcCtD
Everolimus—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000342	CcSEcCtD
Everolimus—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000341	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	0.000136	0.000964	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000339	CcSEcCtD
Everolimus—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000338	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000135	0.000953	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB3—chronic obstructive pulmonary disease	0.000135	0.000953	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB3—chronic obstructive pulmonary disease	0.000134	0.000949	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000332	CcSEcCtD
Everolimus—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000328	CcSEcCtD
Everolimus—Infection—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000326	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	0.00013	0.00092	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	0.00013	0.000916	CbGpPWpGaD
Everolimus—Shock—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000322	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	0.000129	0.000911	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000129	0.00091	CbGpPWpGaD
Everolimus—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000321	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CRP—chronic obstructive pulmonary disease	0.000128	0.000907	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—chronic obstructive pulmonary disease	0.000128	0.000907	CbGpPWpGaD
Everolimus—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00032	CcSEcCtD
Everolimus—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000318	CcSEcCtD
Everolimus—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000317	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—chronic obstructive pulmonary disease	0.000127	0.000896	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000126	0.000886	CbGpPWpGaD
Everolimus—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000312	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TLR4—chronic obstructive pulmonary disease	0.000123	0.00087	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	0.000121	0.000853	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—chronic obstructive pulmonary disease	0.000121	0.000853	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	0.000121	0.000853	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	0.00012	0.000845	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000299	CcSEcCtD
Everolimus—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00012	0.000298	CcSEcCtD
Everolimus—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000296	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	0.000119	0.000838	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	0.000118	0.000834	CbGpPWpGaD
Everolimus—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000294	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000116	0.00082	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR2—chronic obstructive pulmonary disease	0.000116	0.00082	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000116	0.000818	CbGpPWpGaD
Everolimus—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000288	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000115	0.000809	CbGpPWpGaD
Everolimus—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000285	CcSEcCtD
Everolimus—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000284	CcSEcCtD
Everolimus—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000284	CcSEcCtD
Everolimus—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000283	CcSEcCtD
Everolimus—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.000282	CcSEcCtD
Everolimus—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000112	0.00028	CcSEcCtD
Everolimus—FKBP1A—Disease—NOS2—chronic obstructive pulmonary disease	0.000112	0.000791	CbGpPWpGaD
Everolimus—MTOR—Immune System—KL—chronic obstructive pulmonary disease	0.000109	0.000771	CbGpPWpGaD
Everolimus—MTOR—Disease—HDAC2—chronic obstructive pulmonary disease	0.000108	0.000766	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000108	0.00027	CcSEcCtD
Everolimus—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000268	CcSEcCtD
Everolimus—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000268	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	0.000107	0.000756	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	0.000107	0.000756	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000107	0.000754	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000105	0.000743	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000104	0.000733	CbGpPWpGaD
Everolimus—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000259	CcSEcCtD
Everolimus—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000259	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000104	0.000731	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000101	0.000715	CbGpPWpGaD
Everolimus—MTOR—Disease—KL—chronic obstructive pulmonary disease	0.000101	0.000712	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	9.98e-05	0.000705	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	9.68e-05	0.000241	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—chronic obstructive pulmonary disease	9.59e-05	0.000677	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—chronic obstructive pulmonary disease	9.43e-05	0.000666	CbGpPWpGaD
Everolimus—Asthenia—Prednisone—chronic obstructive pulmonary disease	9.42e-05	0.000235	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.41e-05	0.000664	CbGpPWpGaD
Everolimus—Pruritus—Prednisone—chronic obstructive pulmonary disease	9.29e-05	0.000232	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.06e-05	0.000639	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—chronic obstructive pulmonary disease	9.01e-05	0.000636	CbGpPWpGaD
Everolimus—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	8.99e-05	0.000224	CcSEcCtD
Everolimus—MTOR—Immune System—CD8A—chronic obstructive pulmonary disease	8.8e-05	0.000621	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—chronic obstructive pulmonary disease	8.77e-05	0.00062	CbGpPWpGaD
Everolimus—Dizziness—Prednisone—chronic obstructive pulmonary disease	8.68e-05	0.000217	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.42e-05	0.000594	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—chronic obstructive pulmonary disease	8.35e-05	0.000208	CcSEcCtD
Everolimus—Rash—Prednisone—chronic obstructive pulmonary disease	8.28e-05	0.000207	CcSEcCtD
Everolimus—Dermatitis—Prednisone—chronic obstructive pulmonary disease	8.27e-05	0.000206	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IL6—chronic obstructive pulmonary disease	8.23e-05	0.000581	CbGpPWpGaD
Everolimus—Headache—Prednisone—chronic obstructive pulmonary disease	8.23e-05	0.000205	CcSEcCtD
Everolimus—MTOR—Immune System—ERBB3—chronic obstructive pulmonary disease	8.19e-05	0.000578	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	8.14e-05	0.000575	CbGpPWpGaD
Everolimus—Nausea—Prednisone—chronic obstructive pulmonary disease	7.8e-05	0.000195	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	7.59e-05	0.000536	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB3—chronic obstructive pulmonary disease	7.56e-05	0.000534	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—chronic obstructive pulmonary disease	7.48e-05	0.000528	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—chronic obstructive pulmonary disease	7.17e-05	0.000507	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.06e-05	0.000498	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.61e-05	0.000466	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.52e-05	0.00046	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.31e-05	0.000445	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—chronic obstructive pulmonary disease	6.3e-05	0.000445	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—chronic obstructive pulmonary disease	6.11e-05	0.000431	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—chronic obstructive pulmonary disease	5.96e-05	0.000421	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	5.86e-05	0.000414	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—chronic obstructive pulmonary disease	5.84e-05	0.000412	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.82e-05	0.000411	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.59e-05	0.000395	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.39e-05	0.000381	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—chronic obstructive pulmonary disease	5.31e-05	0.000375	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.29e-05	0.000374	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	5.25e-05	0.00037	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.09e-05	0.00036	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—chronic obstructive pulmonary disease	5.07e-05	0.000358	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.06e-05	0.000357	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.88e-05	0.000344	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.74e-05	0.000334	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—chronic obstructive pulmonary disease	4.69e-05	0.000331	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—chronic obstructive pulmonary disease	4.67e-05	0.00033	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.54e-05	0.000321	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—chronic obstructive pulmonary disease	4.49e-05	0.000317	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.17e-05	0.000295	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.09e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.72e-05	0.000262	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—chronic obstructive pulmonary disease	3.56e-05	0.000251	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.55e-05	0.00025	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.43e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—chronic obstructive pulmonary disease	3.35e-05	0.000237	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—chronic obstructive pulmonary disease	3.28e-05	0.000232	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.15e-05	0.000222	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.14e-05	0.000222	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.87e-05	0.000202	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.85e-05	0.000201	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.83e-05	0.0002	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—chronic obstructive pulmonary disease	2.73e-05	0.000193	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.59e-05	0.000183	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.56e-05	0.00018	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—chronic obstructive pulmonary disease	2.52e-05	0.000178	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.38e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.35e-05	0.000166	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.3e-05	0.000162	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.99e-05	0.00014	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.96e-05	0.000138	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.93e-05	0.000136	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.83e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.77e-05	0.000125	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.73e-05	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.18e-05	8.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.13e-05	7.95e-05	CbGpPWpGaD
